Prostigmin

Prostigmin

neostigmine

Manufacturer:

Transfarma Medica Indah

Marketer:

A Menarini
Concise Prescribing Info
Contents
Neostigmine methylsulfate
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Symptomatic control of myasthenia gravis 1 mL (0.5 mg) SC/IM, subsequent doses based on individual's response. Prevention of post-op distension & urinary retention 0.5 mL (0.25 mg) SC/IM immediately post-op. Repeat 4-6 hrly for 2-3 days. Treatment of post-op distension 1 mL (0.5 mg) SC/IM as required. Treatment of urinary retention 1 mL (0.5 mg) SC/IM. If urine does not occur w/in 1 hr, patient should be catheterized. After the bladder has been emptied, continue w/ 0.5 mg inj 3 hrly for at least 5 inj. Reversal of nondepolarizing neuromuscular blockade 0.5-2 mg slow IV, repeated as required.
Contraindications
Mechanical intestinal or urinary tract obstruction, peritonitis.
Special Precautions
Bronchial asthma, vagotonia; recent coronary occlusion; hypotension; bradycardia; peptic ulcer; epilepsy; hyperthyroidism, CV disorders, renal impairment. Co-administration w/ anticholinergic agents. Pregnancy & lactation.
Adverse Reactions
Salivation, fasciculation, dizziness, convulsions, drowsiness, headache, dysarthria, visual disturbances, cardiac arrhythmias, syncope. Increased mucous membrane secretion, resp arrest, bronchospasm, nausea, emesis, GI & urinary tract spasm & hypermotility.
Drug Interactions
Neomycin, streptomycin, kanamycin, local & general anesth, antiarrhythmic agents.
MIMS Class
Neuromuscular Disorder Drugs
ATC Classification
N07AA01 - neostigmine ; Belongs to the class of anticholinesterase. Used as parasympathomimetics.
Presentation/Packing
Form
Prostigmin inj 0.5 mg/mL
Packing/Price
5 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in